Kairos Pharma, Ltd. (KAPA)

Official site

HEALTHCARE • BIOTECHNOLOGY • AMEX

$0.66

-0.08 (-10.86%)

Market Cap: $2.52M

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

25%(2/8)

Avg Surprise

-121.79%

Streak

1 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.63

Range$-0.63 - $-0.63

1 analysts

EPS RevisionsNo revisions (7d)No revisions (30d)

EPS Estimate DriftChange to current

90d ago$-0.630.0%

60d ago$-0.630.0%

30d ago$-0.630.0%

7d ago$-0.630.0%

Current$-0.63

Revenue Consensus

Range$0 - $0

2 analysts

Period ending Dec 31, 2026

EPS Consensus$-1.80

Range$-1.80 - $-1.80

1 analysts

Revenue Consensus

Range$0 - $0

2 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-1.80	$-1.80 - $-1.80	-	-	1	-	-
Sep 30, 2026Sep 26EST	-	$-0.63	$-0.63 - $-0.63	-	-	1	No revisions (30d)	-
Jun 30, 2026Jun 26 Reported Aug 12, 2026Reported Aug 12	$-0.06	$-0.09	$-0.09 - $-0.09	+33.33%	Beat	1	No revisions (30d)	+25.0%
Mar 31, 2026Mar 26 Reported May 13, 2026Reported May 13	$-0.08	$-0.07	$-0.07 - $-0.07	-14.29%	Miss	1	No revisions (30d)	-166.7%
Dec 31, 2025Dec 25 Reported Mar 31, 2026Reported Mar 31	$-0.07	$0.03	$0.03 - $0.03	-333.33%	Miss	1	No revisions (30d)	-40.0%
Sep 30, 2025Sep 25 Reported Nov 14, 2025Reported Nov 14	$-0.07	$-0.07	$-0.10 - $-0.05	+0.00%	Beat	2	No revisions (30d)	+30.0%
Jun 30, 2025Jun 25 Reported Aug 12, 2025Reported Aug 12	$-0.08	$-0.05	$-0.05 - $-0.05	-60.00%	Miss	1	No revisions (30d)	-300.0%
Mar 31, 2025Mar 25 Reported Apr 15, 2025Reported Apr 15	$-0.03	$-0.02	-	-50.00%	Miss	-	-	-
Dec 31, 2024Dec 24 Reported Feb 26, 2025Reported Feb 26	$-0.05	$-0.02	$-0.02 - $-0.02	-150.00%	Miss	1	No revisions (30d)	-
Sep 30, 2024Sep 24 Reported Nov 14, 2024Reported Nov 14	$-0.10	$-0.02	-	-400.00%	Miss	-	-	-
Jun 30, 2024Jun 24 Reported Aug 28, 2024Reported Aug 28	$-0.02	$0.00	-	N/A	Miss	-	-	-

Key Metrics

Valuation
P/E Ratio	-0.34	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-114.00%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	N/A
Current Ratio	11.98x	Quick Ratio	11.98x
Trading Statistics
Beta	1.44	Avg Volume	898.70K
52-Week High	$8.53	52-Week Low	$0.71

Technical Indicators Dashboard

Moving Averages

SMA 10$1.00

SMA 20$1.35

SMA 50$1.73

SMA 200$3.33

EMA 10$0.97

EMA 20$1.23

EMA 50$1.65

EMA 200$3.20

MACD

Line: -0.30Signal: -0.23Hist: -0.07

ADX

ADX: 36.0+DI: 13.8-DI: 11.9

Aroon & PSAR

Aroon Up72.0

Aroon Down100.0

PSAR$1.68

Bollinger Bands

Upper Band$2.21

Lower Band$0.49

%B Position12693%(Upper)

Band Width0.10

RSI (14-Day)

Oversold

18.7

Momentum Oscillators

Stoch %K3.0

Stoch %D4.3

Williams %R-99.6

ROC (10d)-57.5%

Momentum-0.90

CCI (20d)-123.9

MFI (14d)26.6

Volatility Measures

ATR (14d)$0.34(51.7%)

StdDev (20d)0.43

Hist Vol142.2%(High)

Volume Flow

VWAP$0.68

OBV198.2M

AD Line33.5B

CMF (20d)-0.712

Volume Metrics

Avg Vol (20d)986.6K

Vol Ratio0.3x(Low)

VWMA (20d)$1.09

Pivot Points

R3$0.89

R2$0.85

R1$0.79

Pivot Point$0.75

S1$0.70

S2$0.66

S3$0.61

Advanced Oscillators

TSI-51.75

Ultimate Osc24.2

KST-415.82

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Cost of Revenue	$0	$0	$-120,000	$0	$0	$0	N/A	$0	$0	$0	$40,000	$0
Gross Profit	$0	$0	$120,000	$0	$0	$0	N/A	$0	$0	$0	$-40,000	$0

Operating Expenses	$1.42M	$1.69M	$1.42M	$1.44M	$1.46M	$1.27M	$1.45M	$383,000	$222,000	$287,000	$1.05M	$287,000
R&D	$619,000	$684,000	$538,000	$608,000	$496,000	$493,000	$172,000	$14,000	$63,000	$165,000	$7,000	$33,000
SG&A	$798,000	$1.01M	$877,000	$827,000	$960,000	$773,000	$1.28M	$369,000	$159,000	$122,000	$1.04M	$254,000
Operating Income	$-1,417,000	$-1,690,000	$-1,415,000	$-1,435,000	$-1,456,000	$-1,266,000	$-1,451,000	$-383,000	$-222,000	$-287,000	$-1,089,000	$-287,000

Interest Income	$0	$0	$50,000	$37,000	$0	$0	$0	$0	$0	$0	$0	$0
Interest Expense	$0	$0	$0	$0	$0	$0	$-5,000	$127,000	$31,000	$36,000	$29,000	$25,000
Income Before Tax	$-1,388,000	$-1,654,000	$-1,365,000	$-1,398,000	$-1,422,000	$-1,262,000	$-980,000	$-1,047,000	$-253,000	$-323,000	$-1,118,000	$-312,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-1,388,000	$-1,654,000	$-1,365,000	$-1,398,000	$-1,422,000	$-1,262,000	$-980,000	$-1,047,000	$-253,000	$-323,000	$-1,118,000	$-312,000

EBITDA	$-1,182,000	$-1,430,000	$-1,163,000	$-735,000	$-118,000	$-1,226,000	$-1,411,000	$-765,000	$-143,000	$-247,000	$-1,049,000	$-287,000
EBIT	$-1,417,000	$-1,690,000	$-1,415,000	$-1,435,000	$-1,456,000	$-1,266,000	$-1,451,000	$-920,000	$-222,000	$-287,000	$-1,089,000	$-287,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about KAPA

News

Kairos Pharma reports positive Phase 2 interim PFS data; median PFS 17.7 vs 2 months

Kairos Pharma (KAPA) announced positive interim results from its Phase 2 trial, showing a median Progression-Free Survival (PFS) of 17.7 months for patients treated with ENV-105 plus apalutamide...

TradingView•Oct 7, 2026 2:44 AM ET10/7/26•Bullish

Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer

Kairos Pharma announced positive interim efficacy data from its Phase 2 trial of ENV-105 (carotuximab) in combination with apalutamide for metastatic castration-resistant prostate cancer...

Lelezard•Oct 6, 2026 11:54 PM ET10/6/26•Bullish

Why Is Kairos Pharma Stock Falling Today? - Kairos Pharma (AMEX:KAPA)

Kairos Pharma stock is falling today despite promising interim Phase 2 clinical trial results for ENV-105 in combination with apalutamide for metastatic castration-resistant prostate cancer. The combination therapy...

Benzinga•Oct 6, 2026 2:25 PM ET10/6/26•Bearish

Kairos Pharma, Ltd. (KAPA) Stock Price, News, Quote & History

This Yahoo Finance page provides a comprehensive overview of Kairos Pharma, Ltd. (KAPA) stock, including its current price, historical data...

Yahoo! Finance Canada•Oct 6, 2026 7:58 AM ET10/6/26•Somewhat-Bullish

Kairos Pharma, Ltd. (KAPA) Stock Price & News

This article provides an overview of Kairos Pharma, Ltd. (KAPA) stock, including its current trading price of US$1.72, market capitalization of US$6.87M, and a 52-week range. It highlights recent company news...

Syfe•Sep 24, 2026 9:48 AM ET9/24/26•Neutral

KAPA Valuation and Fair Value

P/E: -0.3x
P/B: 0.5x

See GNG's fair value

KAPA Profitability: Margins, ROIC and FCF

Operating margin: 0.0%
Net margin: 0.0%
ROE: -114.0%

KAPA Competitors

Company	Ticker
Biomotion Sciences Ordinary Shares	SLXN
Matinas BioPharma Holdings Inc	MTNB
iSpecimen Inc	ISPC
GeoVax Labs Inc	GOVX
Nexalin Technology Inc.	NXL
Elevai Labs, Inc. Common Stock	ELAB
VivoSim Labs, Inc.	VIVS
Flora Growth Corp	FLGC

Sector: Healthcare

KAPA Bull Case vs Bear Case

Bear case

KAPA beat EPS estimates in 12.5% of its last 8 reported quarters.

KAPA Earnings: Beat Rate and Next Report

Beat rate: 1 of 8 quarters (12.5%)
Average surprise: -121.8%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.63
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 0 up, 0 down

Frequently Asked Questions About KAPA

Does KAPA pay dividends?

Kairos Pharma, Ltd. (KAPA) does not currently pay a regular dividend.

What is KAPA's market cap?

Kairos Pharma, Ltd. (KAPA) has a market capitalization of $2.52M with a current stock price of $0.66.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In